Trends in the Surgical Management of Crohn’s Disease

Journal of Gastrointestinal Surgery

Volumn 19, Issue 10, 2015, Pages 1862-1868

  Geltzeiler, Cristina B ^a   Hart, Kyle D ^a   Lu, Kim C ^a   Deveney, Karen E ^a   Herzig, Daniel O ^a   Tsikitis, Vassiliki L ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Crohn s Disease; Crohn s related surgical interventions; Perianal fistulizing disease; Stoma constructions

Indexed keywords

ADULT; COLOSTOMY; COMPLICATION; CROHN DISEASE; FACTUAL DATABASE; FEMALE; HUMAN; ILEOSTOMY; INTESTINAL FISTULA; MALE; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; TRENDS; UNITED STATES; WEIGHT REDUCTION;

ADULT; COLOSTOMY; CROHN DISEASE; DATABASES, FACTUAL; FEMALE; HUMANS; ILEOSTOMY; INTESTINAL FISTULA; MALE; MIDDLE AGED; UNITED STATES; WEIGHT LOSS;

EID: 84942505482     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-015-2911-3     Document Type: Article

References (33)

1. Kornbluth A. Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference. Inflamm Bowel Dis 1998;4:328–9.
2. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF Rachmilewitz, D, Wolf DC, Olson A, Bao W, Rutgeerts P. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541–9
3. Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004;99: 91–6.
4. Costa J, Magro F, Caldeira D, Alarcao J, Sousa R, Vaz-Carneiro A. Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2013;19:2098–110.
5. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and recurrence in 907 patients with primary ileocaecal Crohn's disease. Br J Surg., 2000. 87(12): p. 1697–701.
6. Farmer RG, Whelan G, Fazio VW. Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis. Gastroenterology 1985;88:1818–25.
7. Fielding JF, Collins PG, Lane BE, Osborne HD. Surgery for Crohn's disease in Ireland. Dis Colon Rectum 1986;29: 230–3.
8. Heimann TM, Greenstein AJ, Lewis B, Kaufman D, Heimann DM, Aufses Jr AH. Comparison of primary and reoperative surgery in patients with Crohns disease. Ann Surg 1998;227:492–5.
9. Truelove SC, Pena SC. Course and prognosis of Crohn's disease. Gut 1976;17:192–201.
10. Bouguen G, Peyrin-Biroulet L. Surgery for adult Crohn's disease: what is the actual risk? Gut 2011;60:1178–81.
11. Peyrin-Biroulet L, Oussalah A, Williet N, Pillot C, Bresler L, Bigard MA. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 2011;60:930–6.
12. Samimi R, Flasar MH, Kavic S, Tracy K, Cross RK. Outcome of medical treatment of stricturing and penetrating Crohn's disease: a retrospective study. Inflamm Bowel Dis 2010;16:1187–94.
13. Drossman DA, Patrick DL, Mitchell CM, Zagami EA, Appelbaum MI. Health-related quality of life in inflammatory bowel disease. Functional status and patient worries and concerns. Dig Dis Sci 1989;34:1379–86.
14. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiert E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005;54:237–41.
15. Coscia M, Gentilini L, Laureti S, Gionchetti P, Rizzello F, Campieri M, Calabrese C, Poggioli G. Risk of permanent stoma in extensive Crohn's colitis: the impact of biological drugs. Colorectal Dis 2013;15:1115–22.
16. Agency for Health Care Research and Quality. Introduction to the HCUP Nationwide Inpatient Sample 2013. [Accessed 12/19/2013]; Available from: http://www.hcup-us.ahrq.gov
17. RC Team. R: A Language and Environment for Statistical Computing, 2014.
18. TL. Analysis of Complex Survey Samples. J Statistical Software, 2004. 9: p. 1–19
19. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011. 140: 1785–94.
20. Jess T, Riis L, Vind I, Winther KV, Borg S, Binder V, Langholtz E, Thomsen OO, Munkholm P. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis 2007;13:481–9.
21. Loftus CG, Loftus Jr EV, Harmsen WS, Zinsmeister AR, Tremaine WJ, Melton III LJ, Sandborn WJ. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. Inflamm Bowel Dis 2007;13:254–61.
22. Molodecky NA, Soon IS, Rabi DM, Ghai WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46–54.e42; quiz e30
23. Vind I, Riis L, Jess T, Knudsen E, Pedersen N, Elkjaer M, Bak Andersen I, Wewer V, Norregaard P, Moesgaard F, Bendtsen F, Munkholm P. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003–2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006;101:1274–82.
24. Loftus Jr EV. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504–17.
25. Wolters FL, Russel MG, Stockbrugger RW. Systematic review: has disease outcome in Crohn's disease changed during the last four decades? Aliment Pharmacol Ther 2004;20:483–96.
26. Geltzeiler CB, Lu KC, Diggs BS, Deveney KE, Keyashian K, Herzig DO, Tsikitis VL. Initial surgical management of ulcerative colitis in the biologic era. Dis Colon Rectum 2014;57:1358–63.
27. El-Hussuna A, Krag A, Olaison G, Bendtsen F, Gluud LL. The effect of anti-tumor necrosis factor alpha agents on postoperative anastomotic complications in Crohn's disease: a systematic review. Dis Colon Rectum 2013;56:1423–33.
28. Yang ZP, Hong L, Wu Q, Wu KC, Fan DM. Preoperative infliximab use and postoperative complications in Crohn's disease: a systematic review and meta-analysis. Int J Surg, 2014;12:224–30.
29. Brooks M. Top Selling Drugs of 2013. Medscape Multispecialty- News and Perspective 2014 [Accessed 06/29/15]; Available from: http://www.medscape.com/viewarticle/820011.
30. Alos R, Hinojosa J. Timing of surgery in Crohn's disease: a key issue in the management. World J Gastroenterol 2008;14:5532–9.
31. Gu J, Valente MA, Rezmi FH, Stocchi L. Factors affecting the fate of faecal diversion in patients with perianal Crohn's disease. Colorectal Dis 2015;17:66–72.
32. Knowles SR, Wilson J, Wilkinson A, Connell W, Saltzberg M, Castle D, Desmond P, Kamm MA. Psychological well-being and quality of life in Crohn's disease patients with an ostomy: a preliminary investigation. J Wound Ostomy Continence Nurs, 2013;40:623–9.
33. Zerbib P, Koriche D, Truant S, Bouras AF, Vernier-Massouille G, Seguy D, Pruvot FR, Cortot A, Colombel JF. Pre-operative management is associated with low rate of post-operative morbidity in penetrating Crohn's disease. Aliment Pharmacol Ther 2010;32:459–65.